Elizabeth Thiele, MD
Neurology with Special Qualifications in Child Neurology · Boston, MANPI 1982670535
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $219,591 of the $277,849 with a category attached, or 79.0%. 24 manufacturers reported payments, led by Greenwich Biosciences, Inc. at 30.2% of the total. Reporting peaked in 2019 at $80,053 and has fallen 55.5% since, to $35,656 in 2025. Among neurology with special qualifications in child neurology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $1208.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Greenwich Biosciences, Inc.$84K
- Jazz Pharmaceuticals Inc.$55K
- UCB, Inc.$32K
- GW Pharma Limited$27K
- Takeda Pharmaceuticals U.S.A., Inc.$19K
- GW Research Limited$10K
- plus $50K from 18 others
Across 64 payments — averaging $17,667 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GW Research Limited$693K
- Jazz Pharmaceuticals Inc.$133K
- UCB, Inc.$94K
- UCB SA$92K
- Zogenix Inc.$73K
- H. Lundbeck A S$22K
- plus $25K from 2 others
What the payments were for
- Consulting fees$219,59179%
- Speaking & faculty fees$29,91211%
- Travel & lodging$23,9979%
- Food & beverage$4,3232%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Greenwich Biosciences, Inc. | 53 | $84,007 |
| Jazz Pharmaceuticals Inc. | 46 | $55,204 |
| UCB, Inc. | 57 | $32,106 |
| GW Pharma Limited | 7 | $27,371 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $19,499 |
| GW Research Limited | 6 | $9,871 |
| Livanova USA, Inc. | 7 | $6,595 |
| Radius Health, Inc. | 4 | $6,365 |
| Zogenix Inc. | 5 | $6,312 |
| Biocodex, Inc. | 7 | $6,248 |
| UCB SA | 1 | $4,803 |
| Lundbeck LLC | 2 | $3,919 |
| BTG International Inc. | 4 | $2,941 |
| Eisai CO., LTD. | 1 | $2,400 |
| Aquestive Therapeutics, Inc. | 3 | $2,040 |
| Immedica Pharma US, Inc. | 2 | $1,909 |
| West Therapeutics Development, LLC | 2 | $1,750 |
| Eisai Inc. | 1 | $1,680 |
| Nobelpharma America, LLC | 1 | $1,290 |
| Azurity Pharmaceuticals, Inc. | 1 | $1,200 |
| SK Life Science, Inc. | 2 | $226 |
| Cadwell Industries, Inc | 1 | $66 |
| Merck | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$142,850
- Fintepla$23,083
- DIACOMIT$6,088
- VNS - Sentiva$4,587
- Fycompa$4,080
- Vimpat$3,526
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$2,008
- ZTALMY$1,909
- HYFTOR$1,290
- SYMPAZAN$1,020
How this compares
$277,849 in reported general payments places this provider in the 95th percentile of 101 neurology with special qualifications in child neurology providers in Massachusetts.
See all neurology with special qualifications in child neurology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 229 | $1,373,739 |
| Vigabatrin | 29 | $321,366 |
| FinteplaFenfluramine Hcl | 14 | $273,736 |
| XcopriCenobamate | 194 | $255,282 |
| Lamictal XrLamotrigine | 83 | $243,894 |
| OnfiClobazam | 44 | $159,324 |
| HyftorSirolimus | 36 | $144,166 |
| NayzilamMidazolam | 65 | $130,367 |
| KeppraLevetiracetam | 71 | $127,234 |
| TopamaxTopiramate | 13 | $80,925 |
| AptiomEslicarbazepine Acetate | 34 | $75,023 |
| VimpatLacosamide | 41 | $44,821 |
| Clobazam | 279 | $36,178 |
| NeurontinGabapentin | 13 | $34,947 |
| Depakote SprinkleDivalproex Sodium | 27 | $32,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Nayzilam, Vimpat | $32,106 | $448,924120 claims |
| SK Life Science, Inc.Xcopri | $226 | $255,282194 claims |
| Lundbeck LLCOnfi | $3,919 | $159,32444 claims |
| Nobelpharma America, LLCHyftor | $1,290 | $144,16636 claims |
| UCB SAKeppra | $4,803 | $127,23471 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $22 | $75,02334 claims |
| Eisai Inc.Fycompa | $1,680 | $18,79915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 neurology with special qualifications in child neurology providers in Massachusetts.
Other neurology with special qualifications in child neurology in Boston
- Jurriaan PetersBoston$265K
- Basil DarrasBoston$253K
- Kiran MaskiBoston$105K
- Phillip PearlBoston$50K
- Alexander RotenbergBoston$34K
- Irina AnselmBoston$30K
- Nicole UllrichBoston$26K
- David LiebermanBoston$19K
- Robert StoweBoston$9K
- Siddharth SrivastavaBoston$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.